Shuttle Pharmaceuticals Holdings, Inc. (SHPH) shareholders
Close on Nov 13, 2026Market cap $4.54MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SHPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 78,597 | 1.65% | $255.00K | New | 0.00% |
| Citadel Advisors LLC | 24,354 | 0.51% | $79.15K | New | 0.00% |
| Barclays PLC | 750 | 0.02% | $2.44K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 389 | 0.01% | $1.26K | New | 0.00% |
| Wall Street Access Asset Management, LLC | 120 | 0.00% | $390 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 0M | 2.2% | 5 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SHPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | -100 | -0.00% | -$325 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan Trasolini | Co-Chief Executive Officer | – | – | Jun 1, 2026 |
| Yuying Liang | Chief Financial Officer | – | – | Jan 12, 2026 |
| Timothy J. Lorber | Chief Financial Officer | 227,635 | 4.78% | Aug 12, 2025 |
| Chris Cooper | Interim Co-CEO | – | – | Apr 2, 2025 |
| Angel Liriano | Director | 0 | – | Oct 29, 2025 |
| Arachchige Sachin Eranga Pathigoda | Director | 0 | – | Oct 28, 2025 |
| Adam V. Chambers | Director | 0 | – | Sep 8, 2025 |
| Steven M. Richards | Director | 210,004 | 4.41% | Aug 13, 2025 |
| Joseph Tung | Director | 184,162 | 3.87% | Aug 12, 2025 |
| George Scorsis | Director | 184,162 | 3.87% | Aug 12, 2025 |
| Oleh Nabyt | Director | 184,162 | 3.87% | Aug 12, 2025 |
| Joshua Schafer | Director | 210,004 | 4.41% | Feb 6, 2025 |
| Milton Brown | Director | 346,617 | 7.27% | Feb 5, 2025 |
| Financial Lp Hrt | 10% owner | 0 | – | Jul 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Financial Lp Hrt 10% owner | Jul 14, 2026 | Sale | −82,116 | $4.48 | $367.88K | 0 |
| Financial Lp Hrt 10% owner | Jul 13, 2026 | Sale | −1,033 | $4.67 | $4.82K | 60,238 |
| Financial Lp Hrt 10% owner | Jul 10, 2026 | Buy | +731 | $3.11 | $2.27K | 61,271 |
| Financial Lp Hrt 10% owner | Jul 9, 2026 | Buy | +8,266 | $3.38 | $27.94K | 60,540 |
| Financial Lp Hrt 10% owner | Jul 8, 2026 | Sale | −18,531 | $3.52 | $65.23K | 52,274 |
| Financial Lp Hrt 10% owner | Jul 7, 2026 | Sale | −10,580 | $3.33 | $35.23K | 70,805 |
| Financial Lp Hrt 10% owner | Jul 6, 2026 | Sale | −9,022 | $3.51 | $31.67K | 81,385 |
| Financial Lp Hrt 10% owner | Jul 2, 2026 | Buy | +7,851 | $3.54 | $27.79K | 90,407 |
| Financial Lp Hrt 10% owner | Jul 1, 2026 | Buy | +3,959 | $3.30 | $13.06K | 82,556 |
| Financial Lp Hrt 10% owner | Jun 30, 2026 | Buy | +6,755 | $3.23 | $21.82K | 78,597 |
| Financial Lp Hrt 10% owner | Jun 29, 2026 | Buy | +25,836 | $3.44 | $88.88K | 71,842 |
| Joshua Schafer Director | Dec 31, 2024 | Award | +209,790 | – | – | 210,004 |
| Steven M. Richards Director | Dec 31, 2024 | Award | +209,790 | – | – | 210,004 |
| Steven M. Richards Director | Dec 23, 2024 | Award | +209,790 | – | – | 210,004 |
| Joshua Schafer Director | Dec 23, 2024 | Award | +209,790 | – | – | 210,004 |
| Milton Brown Director | Dec 23, 2024 | Award | +209,790 | – | – | 346,617 |
| Mira Jung Chief Scientific Officer | May 1, 2024 | Award | −598 | $11.28 | $6.75K | 135,715 |
| Hoek Michael Vander Chief Financial Officer | Mar 8, 2024 | Award | +100,000 | – | – | 103,852 |
| Milton Brown Director | Dec 13, 2023 | Sale | −2,921 | $0.46 | $1.34K | 1,094,610 |
| Bette Jacobs Director | Dec 13, 2023 | Sale | −4,157 | $0.46 | $1.91K | 27,064 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Aug 14, 2023 | Gift | −2,100,000 | – | – | 1,104,407 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Aug 14, 2023 | Gift | +2,100,000 | – | – | 2,100,000 |
| Chris Senanayake Director | Dec 29, 2022 | Sale | −1,626 | $1.61 | $2.62K | 2,791 |
| Steven M. Richards Director | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 1,707 |
| William Adkins – | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 184,071 |
| Milton Brown Director | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 1,072,531 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Dec 29, 2022 | Sale | −8,372 | $1.61 | $13.48K | 1,085,200 |
| Tyvin Rich Chief Medical Officer | Dec 29, 2022 | Sale | −1,414 | $1.61 | $2.28K | 2,429 |
| Bette Jacobs Director | Dec 29, 2022 | Sale | −4,366 | $1.61 | $7.03K | 31,221 |
| Mira Jung Chief Scientific Officer | Dec 29, 2022 | Sale | −328 | $1.61 | $528 | 1,071,388 |
| Hoek Michael Vander Chief Financial Officer | Dec 29, 2022 | Sale | −2,243 | $1.61 | $3.61K | 3,852 |
| Peter Dritschilo President and COO | Dec 29, 2022 | Sale | −3,820 | $1.61 | $6.15K | 6,560 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Shuttle Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,309 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?